438 related articles for article (PubMed ID: 16179584)
1. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
Keidar S; Gamliel-Lazarovich A; Kaplan M; Pavlotzky E; Hamoud S; Hayek T; Karry R; Abassi Z
Circ Res; 2005 Oct; 97(9):946-53. PubMed ID: 16179584
[TBL] [Abstract][Full Text] [Related]
2. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
Keidar S; Kaplan M; Pavlotzky E; Coleman R; Hayek T; Hamoud S; Aviram M
Circulation; 2004 May; 109(18):2213-20. PubMed ID: 15123520
[TBL] [Abstract][Full Text] [Related]
3. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
4. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes.
Yamamuro M; Yoshimura M; Nakayama M; Abe K; Sumida H; Sugiyama S; Saito Y; Nakao K; Yasue H; Ogawa H
Circ J; 2008 Aug; 72(8):1346-50. PubMed ID: 18654024
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
[TBL] [Abstract][Full Text] [Related]
7. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
8. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
Onozato ML; Tojo A; Kobayashi N; Goto A; Matsuoka H; Fujita T
Nephrol Dial Transplant; 2007 May; 22(5):1314-22. PubMed ID: 17324946
[TBL] [Abstract][Full Text] [Related]
9. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
Karram T; Abbasi A; Keidar S; Golomb E; Hochberg I; Winaver J; Hoffman A; Abassi Z
Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1351-8. PubMed ID: 15894569
[TBL] [Abstract][Full Text] [Related]
10. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.
Macdonald JE; Kennedy N; Struthers AD
Heart; 2004 Jul; 90(7):765-70. PubMed ID: 15201246
[TBL] [Abstract][Full Text] [Related]
11. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
[TBL] [Abstract][Full Text] [Related]
12. Role of angiotensin-converting enzyme (ACE and ACE2) imbalance on tourniquet-induced remote kidney injury in a mouse hindlimb ischemia-reperfusion model.
Yang XH; Wang YH; Wang JJ; Liu YC; Deng W; Qin C; Gao JL; Zhang LY
Peptides; 2012 Jul; 36(1):60-70. PubMed ID: 22580272
[TBL] [Abstract][Full Text] [Related]
13. The role of aldosterone and aldosterone-receptor antagonists in heart failure.
Khan NU; Movahed A
Rev Cardiovasc Med; 2004; 5(2):71-81. PubMed ID: 15184841
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
15. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
16. Role of mineralocorticoid receptor on experimental cerebral aneurysms in rats.
Tada Y; Kitazato KT; Tamura T; Yagi K; Shimada K; Kinouchi T; Satomi J; Nagahiro S
Hypertension; 2009 Sep; 54(3):552-7. PubMed ID: 19620512
[TBL] [Abstract][Full Text] [Related]
17. Balance between angiotensin converting enzyme and angiotensin converting enzyme 2 in patients with chronic heart failure.
Wang J; Li N; Gao F; Song R; Zhu S; Geng Z
J Renin Angiotensin Aldosterone Syst; 2015 Sep; 16(3):553-8. PubMed ID: 25869724
[TBL] [Abstract][Full Text] [Related]
18. Myocardial infarction increases ACE2 expression in rat and humans.
Burrell LM; Risvanis J; Kubota E; Dean RG; MacDonald PS; Lu S; Tikellis C; Grant SL; Lew RA; Smith AI; Cooper ME; Johnston CI
Eur Heart J; 2005 Feb; 26(4):369-75; discussion 322-4. PubMed ID: 15671045
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
Adams KF
Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
[TBL] [Abstract][Full Text] [Related]
20. Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition.
Inaba S; Iwai M; Furuno M; Kanno H; Senba I; Okayama H; Mogi M; Higaki J; Horiuchi M
J Hypertens; 2011 Nov; 29(11):2236-45. PubMed ID: 21946695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
